Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Fayetteville. Study-provided care at no cost to qualified participants.
Access glioblastoma specialists in Fayetteville at no cost
This study follows strict safety protocols and ethical guidelines
All study-related glioblastoma treatment provided free
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomusti
Sponsor: NRG Oncology
Check if you qualify for this glioblastoma clinical trial in Fayetteville, AR
If you're searching for glioblastoma treatment options in Fayetteville, AR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Fayetteville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.